Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03990961 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03990961 is a Phase 2 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 5 participants.
The verdict
NCT03990961, a Phase 2 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-09-04 |
| Est. Completion | 2024-04-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03990961
The ClinicalTrials.gov registry entry for NCT03990961 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT03990961 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03990961 about?
NCT03990961 is a clinical study titled "Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)". A non randomized, unblinded, open label phase 2 study to investigate the efficacy of pembrolizumab in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL) with PD-L1 genetic alterations
What is the current status of trial NCT03990961?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2019-09-04. Estimated completion is 2024-04-01.
What interventions are being tested in trial NCT03990961?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT03990961?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.